Q2 EPS Estimates for Verona Pharma Lifted by HC Wainwright

Verona Pharma plc (NASDAQ:VRNA - Free Report) - Research analysts at HC Wainwright upped their Q2 2025 EPS estimates for shares of Verona Pharma in a note issued to investors on Wednesday, April 30th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.08) per share for the quarter, up from their prior forecast of ($0.16). HC Wainwright has a "Buy" rating and a $85.00 price objective on the stock. The consensus estimate for Verona Pharma's current full-year earnings is ($1.95) per share. HC Wainwright also issued estimates for Verona Pharma's Q3 2025 earnings at $0.08 EPS, FY2025 earnings at ($0.08) EPS, Q1 2026 earnings at $0.40 EPS, Q2 2026 earnings at $0.64 EPS, Q3 2026 earnings at $0.88 EPS and FY2026 earnings at $3.04 EPS.

Several other research firms have also issued reports on VRNA. Roth Capital set a $83.00 target price on shares of Verona Pharma in a research note on Friday, February 28th. Roth Mkm assumed coverage on Verona Pharma in a research report on Friday, January 10th. They set a "buy" rating and a $68.00 price objective on the stock. Cowen started coverage on Verona Pharma in a report on Monday, April 28th. They issued a "buy" rating for the company. Truist Financial reissued a "buy" rating and issued a $57.00 target price (up from $44.00) on shares of Verona Pharma in a report on Wednesday, January 8th. Finally, Canaccord Genuity Group increased their target price on Verona Pharma from $44.00 to $72.00 and gave the company a "buy" rating in a report on Wednesday, February 12th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $81.50.

Verona Pharma Trading Down 0.7 %

NASDAQ VRNA traded down $0.48 during trading hours on Friday, hitting $72.25. 781,830 shares of the company's stock were exchanged, compared to its average volume of 1,268,656. Verona Pharma has a 1-year low of $11.39 and a 1-year high of $74.18. The firm has a market cap of $5.84 billion, a price-to-earnings ratio of -37.63 and a beta of 0.20. The stock has a 50-day simple moving average of $63.10 and a 200 day simple moving average of $52.14. The company has a current ratio of 13.03, a quick ratio of 12.88 and a debt-to-equity ratio of 0.93.

Verona Pharma (NASDAQ:VRNA - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The company reported $0.27 earnings per share for the quarter, topping analysts' consensus estimates of ($0.22) by $0.49. The firm had revenue of $98.65 million for the quarter, compared to the consensus estimate of $41.47 million.

Insider Activity at Verona Pharma

In other news, General Counsel Andrew Fisher sold 26,072 shares of the company's stock in a transaction that occurred on Tuesday, April 29th. The stock was sold at an average price of $8.98, for a total transaction of $234,126.56. Following the completion of the transaction, the general counsel now directly owns 359,993 shares of the company's stock, valued at $3,232,737.14. This represents a 6.75 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO David Zaccardelli sold 90,360 shares of the business's stock in a transaction that occurred on Tuesday, April 29th. The stock was sold at an average price of $8.98, for a total value of $811,432.80. Following the sale, the chief executive officer now owns 14,377,176 shares of the company's stock, valued at $129,107,040.48. The trade was a 0.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 250,080 shares of company stock worth $2,194,582 over the last three months. Company insiders own 4.80% of the company's stock.

Institutional Investors Weigh In On Verona Pharma

Institutional investors have recently made changes to their positions in the stock. NBC Securities Inc. acquired a new position in Verona Pharma during the first quarter worth $34,000. Vermillion Wealth Management Inc. acquired a new position in Verona Pharma during the 4th quarter worth about $46,000. GF Fund Management CO. LTD. purchased a new position in Verona Pharma during the 4th quarter valued at about $72,000. GAMMA Investing LLC grew its position in Verona Pharma by 20.7% in the 4th quarter. GAMMA Investing LLC now owns 1,612 shares of the company's stock valued at $75,000 after acquiring an additional 276 shares in the last quarter. Finally, Avanza Fonder AB purchased a new stake in Verona Pharma during the first quarter worth about $100,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.

About Verona Pharma

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.